Clinical trial
A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following…
NCT00276380 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00276380 |
|---|---|
| Title | A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke |
| Official title | A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761® (Tanakan®) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Stroke, Acute, Neurological Impairment |
| Intervention type | Drug |
| Interventions | EGb761, Placebo, Acetylsalicylic acid |
| Enrollment | 204 |
| Start date | Feb 1, 2003 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Jan 13, 2006 |
| Last update posted | Jan 8, 2019 |
| Countries | Czechia, Poland, Romania, Russia |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: